Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

March 30, 2020April 14, 2020

Oncopeptides’ Accelerated Approval Filing for Melflufen in US Unimpeded by COVID-19

News

Despite some interruptions to melflufen‘s (melphalan flufenamide) clinical program due to the ongoing COVID-19 outbreak, Oncopeptides‘ application seeking its accelerated approval in the U.S. for the treatment of triple-refractory ... Read more

February 28, 2020February 28, 2020

CLR 131 Helps Heavily Treated Multiple Myeloma Patients, Phase 2 Data Show

News

Cellectar Biosciences’ lead candidate CLR 131 safely and effectively prevents disease progression or reduces tumors in people with hard-to-treat multiple myeloma, according to data from a Phase 2 clinical ... Read more

January 31, 2020January 31, 2020

Researchers Provide Highlights on Study into Benefits of Reolysin, Kyprolis Combo in Multiple Myeloma

News

Researchers are continuing to study how the combination of Oncolytics Biotech‘s virus-based anti-cancer therapy Reolysin (pelareorep) and Kyprolis (carfilzomib) provides benefits in multiple myeloma patients, according to a recent conference call. ... Read more

January 6, 2020January 6, 2020

Analysis Group Announces Collaboration to Improve Blood Disease Research and Treatment in China

News

Analysis Group is collaborating with China’s Institute of Hematology & Blood Diseases Hospital (IHBDH) to develop the country’s first blood disorders research platform to analyze real-world data in an ... Read more

November 25, 2019November 25, 2019

BiCNU Generic for Multiple Myeloma, Other Cancers Launched in US

News

Carmustine for Injection, a generic version of the chemotherapy BiCNU, has been launched in the U.S to treat people with multiple myeloma and other types of cancer. This follows ... Read more

November 22, 2019November 22, 2019

Darzalex Triple Combo Approved in Europe for Myeloma Patients Ineligible for ASCT

News

The European Commission has approved Darzalex (daratumumab), in combination with Revlimid (lenalidomide) and dexamethasone, as a first-line treatment for adults with multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The decision was supported ... Read more

November 13, 2019December 19, 2019

CRISPR-edited T-cells Safely, Effectively Target Cancer Cells in Myeloma Patients, Early Phase 1 Data Suggests

News

A new approach using genetically modified T-cells — via CRISPR-Cas9 gene editing technology — safely and effectively targets cancer cells in patients with advanced multiple myeloma, preliminary data from ... Read more

November 6, 2019December 5, 2019

Use of Darzalez and Xpovio Expected to Increase Due to New Approvals, Spherix Survey Shows

News

U.S. blood cancer specialists are aware of recent approvals for multiple myeloma patients and expect to increase their use of Darzalex (daratumumab) as first-line combination therapy, as well as Xpovio ... Read more

October 25, 2019

CHMP Recommends Darzalex Triple Combo for Some Newly Diagnosed Multiple Myeloma Patients in EU

News

The European Medicines Agency (EMA) has recommended that Darzalex (daratumumab) be approved in Europe, in combination with Revlimid (lenalidomide) and dexamethasone, as a first-line treatment for multiple myeloma patients who are ineligible for autologous ... Read more

September 13, 2019

Researchers Identify Promising Target for CAR T-cell Therapy in Myeloma

News

Designing CAR T-cells to specifically target GPRC5D — a protein appreciably present on the surface of myeloma cells — may be a safe and effective therapy against multiple myeloma, a ... Read more

Pin It on Pinterest